Thread by @FrontRowCME

#ESMO22 Presidential Symposium III continued with the eagerly awaited #CodeBreak200 evaluating sotorasib vs docetaxel in pts w/ locally advanced or metastatic KRAS G12C-mutated NSCLC (N=345) presented by @MLJohnsonMD2 from @SarahCannonDocs

#ESMO22 #CodeBreak200 met it's primary EP of improved PFS by BICR with a median f/u of 17.7 mo. Median PFS: 5.6 vs 4.5 mo, HR=0.66, P=.002

#ESMO22 #CodeBreak200 ORR was higher in pts treated with sotorasib (28.1 vs 13.2%) and mDOR was longer with sotorasib (8.6 vs 6.8 mo). There was no difference in OS

#ESMO22 #CodeBreak200 There were fewer gr3 or higher AEs with sotorasib and diarrhea, nausea, and decreased appetite were most common AEs

#ESMO22 #CodeBreak200 PROs favored #sotorasib

#ESMO22 #CodeBreak200 demonstrated that targeting KRAS G12C advanced NSCLC with #sotorasib improved PFS and response although the magnitude of benefit was smaller than anticipated. The study was discussed by Natasha Leighl from @UofT @pmcancercentre

@MLJohnsonMD2 @SarahCannonDocs @threadreaderapp unroll